Drug-Resistant Fungal Disease: A Priority for the 2026 Global Action Plan on AMR

On April 15, 2026, a report published in Nature Medicine emphasized that drug-resistant fungal diseases must be integrated into the 2026 update of the Global Action Plan on Antimicrobial Resistance. The call for action highlights a critical need to address the growing threat of antifungal resistance through a coordinated international strategy.

The push for this inclusion is linked to a proposed five-step global plan designed to combat drug-resistant fungi. According to reports from Medical Xpress, this plan is intended to provide a framework for the World Health Organization as it prepares the 2026 update to its antimicrobial resistance guidelines.

Funding and Concrete Milestones

Experts argue that merely mentioning antifungal resistance is insufficient. The proposed approach insists that the 2026 Global Action Plan must include concrete milestones and dedicated funding to be effective.

Antifungal resistance must be integrated into the 2026 Global Action Plan on AMR, with concrete milestones and funding, or we risk repeating the mistakes made with antibacterial resistance

Medical Xpress

This warning suggests that without specific financial commitments and measurable goals, the global response to fungal resistance may follow the same delayed or inadequate patterns seen in previous efforts to manage antibacterial resistance.

The Evolution of Global Antifungal Strategy

The effort to include fungi in the 2026 update follows a decade of evolving public health focus. The original Global Action Plan on Antimicrobial Resistance was established by the World Health Organization in 2015, primarily focusing on a broader spectrum of antimicrobial threats.

In recent years, the World Health Organization has increasingly targeted fungal pathogens specifically. In 2022, the organization released the WHO Fungal Priority Pathogens List. This list was designed to guide public health action, research, and the development of new treatments by identifying the most urgent fungal threats.

The groundwork for the 2026 update was further strengthened by two key reports released in 2025. One of these documents provided a landscape analysis of commercially available and pipeline in vitro diagnostics for fungal priority pathogens, addressing the need for better identification of resistant strains.

The second 2025 report offered a comprehensive overview and analysis of antifungal agents currently in clinical and preclinical development. Together, these documents provide the technical basis for the specific milestones and funding requests now being advocated for the 2026 Global Action Plan.

Addressing the Gap in Resistance Management

The focus on soil microbiology and biomedicine underscores the complexity of fungal resistance, which often originates or spreads through environmental pathways before affecting human health. By integrating these elements into the 2026 update, health officials aim to close the gap between current capabilities and the rising prevalence of drug-resistant fungal infections.

The proposed overhaul of the worldwide approach to fighting drug-resistant fungi signals a shift toward a more aggressive and structured policy. The objective is to ensure that the 2026 update moves beyond general guidance and establishes a mandatory, funded roadmap for reducing the impact of antifungal resistance on global health.